Dr Christian Klein | Head Oncology Programs
Roche Pharmaceutical Research and Early Development

Dr Christian Klein, Head Oncology Programs, Roche Pharmaceutical Research and Early Development

Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), the preclinical development of four bispecific antibodies currently in active clinical development: 1) CEA-IL2v immunocytokine RG7813 (Ph I), 2) anti-Ang-2/VEGF CrossMAb RG7221 in oncology (Ph II), 3) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I) and 4) CEA-CD3  T cell bispecific antibody RG7802 (Ph I), as well as the development of Roche’s novel proprietary bispecific antibody platforms e.g. the CrossMAb technology.

back to speakers